AR067112A1 - Composicion farmaceutica que comprende 7-(2,5- dihidro -4- imidazo (1,2-a) piridin -3-il-2,5- dioxo-1 h - pirrol 3-il)-9- fluoro-1,2,33,4-tetrahidroo -2-(1- piperidinil-carbonil ) pirrolo (3,2,1-jk) (1,4) benzodiazepina, proceso para su preparacion y uso de la misma para preparar un medicamento - Google Patents
Composicion farmaceutica que comprende 7-(2,5- dihidro -4- imidazo (1,2-a) piridin -3-il-2,5- dioxo-1 h - pirrol 3-il)-9- fluoro-1,2,33,4-tetrahidroo -2-(1- piperidinil-carbonil ) pirrolo (3,2,1-jk) (1,4) benzodiazepina, proceso para su preparacion y uso de la misma para preparar un medicamentoInfo
- Publication number
- AR067112A1 AR067112A1 ARP080102668A ARP080102668A AR067112A1 AR 067112 A1 AR067112 A1 AR 067112A1 AR P080102668 A ARP080102668 A AR P080102668A AR P080102668 A ARP080102668 A AR P080102668A AR 067112 A1 AR067112 A1 AR 067112A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- pharmaceutical composition
- imidazo
- dioxo
- fluoro
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 206010017758 gastric cancer Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 201000011549 stomach cancer Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 abstract 1
- 229960005079 pemetrexed Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94751207P | 2007-07-02 | 2007-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067112A1 true AR067112A1 (es) | 2009-09-30 |
Family
ID=39737054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102668A AR067112A1 (es) | 2007-07-02 | 2008-06-20 | Composicion farmaceutica que comprende 7-(2,5- dihidro -4- imidazo (1,2-a) piridin -3-il-2,5- dioxo-1 h - pirrol 3-il)-9- fluoro-1,2,33,4-tetrahidroo -2-(1- piperidinil-carbonil ) pirrolo (3,2,1-jk) (1,4) benzodiazepina, proceso para su preparacion y uso de la misma para preparar un medicamento |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8318713B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2173348B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5551589B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101230085B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101743005B (cg-RX-API-DMAC7.html) |
| AR (1) | AR067112A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008270732B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0813789A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2691587C (cg-RX-API-DMAC7.html) |
| CL (2) | CL2008001848A1 (cg-RX-API-DMAC7.html) |
| EA (2) | EA023697B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2561202T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL202237A (cg-RX-API-DMAC7.html) |
| MA (1) | MA31677B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009013449A (cg-RX-API-DMAC7.html) |
| MY (1) | MY154472A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ581355A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20090838A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI428132B (cg-RX-API-DMAC7.html) |
| UA (1) | UA97400C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009006043A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200908725B (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
| EP2419106A1 (en) * | 2009-04-14 | 2012-02-22 | Eli Lilly and Company | Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia |
| EP2747761A1 (en) * | 2011-09-22 | 2014-07-02 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
| TW201417817A (zh) * | 2012-09-25 | 2014-05-16 | Daiichi Sankyo Co Ltd | Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合 |
| US20180110780A1 (en) * | 2015-04-30 | 2018-04-26 | Taiho Pharmaceutical Co., Ltd. | Agent for alleviating side effect of antitumor drug |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) * | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10016507B2 (en) * | 2016-03-02 | 2018-07-10 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III |
| AU2017386417B2 (en) * | 2016-12-30 | 2022-07-14 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| WO2022256656A1 (en) * | 2021-06-03 | 2022-12-08 | University Of Cincinnati | Bzd-1 as a chemosensitizer of cancer |
| CN113956157B (zh) * | 2021-11-18 | 2024-05-03 | 西安都创医药科技有限公司 | 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| EP1788086A1 (en) * | 1997-03-17 | 2007-05-23 | Human Genome Sciences, Inc. | Death Domain Containing Receptor 5 |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| EP1483265B1 (en) | 2002-03-05 | 2006-11-22 | Eli Lilly And Company | Purine derivatives as kinase inhibitors |
| ATE378336T1 (de) | 2002-09-19 | 2007-11-15 | Schering Corp | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
| US20110293746A1 (en) * | 2004-07-09 | 2011-12-01 | Agency For Science, Technology And Research | Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders |
| GB0418328D0 (en) * | 2004-08-17 | 2004-09-22 | Imp College Innovations Ltd | Cancer methods and medicaments |
| US20060252082A1 (en) * | 2005-05-04 | 2006-11-09 | University Of South Florida | Predicting treatment response in cancer subjects |
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
-
2008
- 2008-06-18 TW TW097122720A patent/TWI428132B/zh not_active IP Right Cessation
- 2008-06-19 PE PE2008001054A patent/PE20090838A1/es not_active Application Discontinuation
- 2008-06-20 BR BRPI0813789-7A2A patent/BRPI0813789A2/pt not_active IP Right Cessation
- 2008-06-20 CN CN2008800231969A patent/CN101743005B/zh not_active Expired - Fee Related
- 2008-06-20 MY MYPI20095640A patent/MY154472A/en unknown
- 2008-06-20 AR ARP080102668A patent/AR067112A1/es unknown
- 2008-06-20 AU AU2008270732A patent/AU2008270732B2/en not_active Ceased
- 2008-06-20 EA EA201201155A patent/EA023697B1/ru not_active IP Right Cessation
- 2008-06-20 EA EA201070085A patent/EA018447B1/ru not_active IP Right Cessation
- 2008-06-20 EP EP08771559.5A patent/EP2173348B1/en active Active
- 2008-06-20 JP JP2010514996A patent/JP5551589B2/ja not_active Expired - Fee Related
- 2008-06-20 NZ NZ581355A patent/NZ581355A/en not_active IP Right Cessation
- 2008-06-20 MX MX2009013449A patent/MX2009013449A/es active IP Right Grant
- 2008-06-20 US US12/664,664 patent/US8318713B2/en not_active Expired - Fee Related
- 2008-06-20 ES ES08771559.5T patent/ES2561202T3/es active Active
- 2008-06-20 UA UAA200913938A patent/UA97400C2/uk unknown
- 2008-06-20 CN CN2012101150238A patent/CN102772416A/zh active Pending
- 2008-06-20 CL CL2008001848A patent/CL2008001848A1/es unknown
- 2008-06-20 KR KR1020097027543A patent/KR101230085B1/ko not_active Expired - Fee Related
- 2008-06-20 CA CA2691587A patent/CA2691587C/en not_active Expired - Fee Related
- 2008-06-20 WO PCT/US2008/067614 patent/WO2009006043A2/en not_active Ceased
-
2009
- 2009-11-19 IL IL202237A patent/IL202237A/en not_active IP Right Cessation
- 2009-12-08 ZA ZA2009/08725A patent/ZA200908725B/en unknown
-
2010
- 2010-01-27 MA MA32562A patent/MA31677B1/fr unknown
-
2011
- 2011-12-02 CL CL2011003046A patent/CL2011003046A1/es unknown
-
2012
- 2012-03-01 IL IL218443A patent/IL218443A0/en unknown
- 2012-10-18 US US13/654,884 patent/US8648063B2/en not_active Expired - Fee Related
-
2014
- 2014-01-17 JP JP2014006560A patent/JP2014114297A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067112A1 (es) | Composicion farmaceutica que comprende 7-(2,5- dihidro -4- imidazo (1,2-a) piridin -3-il-2,5- dioxo-1 h - pirrol 3-il)-9- fluoro-1,2,33,4-tetrahidroo -2-(1- piperidinil-carbonil ) pirrolo (3,2,1-jk) (1,4) benzodiazepina, proceso para su preparacion y uso de la misma para preparar un medicamento | |
| Hevener et al. | Recent developments in topoisomerase-targeted cancer chemotherapy | |
| JP2010532364A5 (cg-RX-API-DMAC7.html) | ||
| EP2603222B1 (en) | Combinatory cancer treatment | |
| Hande | Topoisomerase II inhibitors | |
| Arnold | Podophyllotoxin derivative VP 16-213 | |
| WO2024189607A1 (en) | Methods and bioavailable highly permeable compounds for diseases treatment | |
| IL196243A (en) | [4,2,1] Triazole [3,4– a Pyridine Derivatives | |
| CN109196103A (zh) | 自组装的3d rna笼形纳米粒 | |
| KR20130114181A (ko) | 체크포인트 키나제 1 억제제 및 wee 1 키나제 억제제의 조합 | |
| KR20120004523A (ko) | Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제 | |
| NO2014028I2 (no) | Glukopyranosyl-substituerte benzenderivater, fremgangsmåte for fremstilling av disse, fysiologisk akseptable salter av slike forbindelser, medikamenter inneholdende slike forbindelser og kombinasjoner med andre aktive substanser samt deresanvendelse for fremstilling av medikamenter for behandling av sykdom | |
| JP2010180210A5 (cg-RX-API-DMAC7.html) | ||
| BR112012030658A2 (pt) | formas de dosagem oral de bendamustina e uso terapêutico da mesma | |
| JP2012524089A5 (cg-RX-API-DMAC7.html) | ||
| Kaur et al. | Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs | |
| CN112601527B (zh) | 用于有效预防和治疗的选择性抗癌剂 | |
| CN113117087A (zh) | 一种药物组合物及其应用 | |
| CN104173288B (zh) | 一种克拉霉素离子对脂质体注射液及其制备方法 | |
| Kanzawa et al. | In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II)(ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line | |
| Miatmoko et al. | Comparative Cellular and In Vivo Anti-cancer studies of Doxorubicin Liposomes Prepared with Different Types of Phospholipids | |
| HK1186130B (en) | Combinatory cancer treatment | |
| HK1186130A (en) | Combinatory cancer treatment | |
| Dombernowsky et al. | The epipodophyllotoxin derivatives VM26 and VP16: experimental and clinical aspects | |
| Saijo | Drug resistance in lung cancer: Topoisomerases as determinants of chemosensitivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |